CagriSema
GLP-1 + amylin · s.c. · Novo Nordisk
Summary
- Also known as
- cagrilintide + semaglutide
- Mechanism
- GLP-1 + amylin
- Route
- s.c.
- Company
- Novo Nordisk
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 (REDEFINE); filing 2026 verify
- Next milestone
- REDEFINE 3 (CV outcomes), REIMAGINE (T2D)
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Positive phase 3; NDA under FDA review (submitted 18 December 2025) | REDEFINE 1; REDEFINE 5; Novo Nordisk release, 18 Dec 2025 |
| T2D | 3 positive phase 3 | Positive phase 3 | REDEFINE 2; REIMAGINE 1 (EASD 2026) |
| CV outcomes | 2 phase 3 ongoing | REDEFINE 3 ongoing | REDEFINE 3 |
| CKD | 1 phase 2 / signal | Phase 2 only | |
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REDEFINE 1 | CagriSema 2.4/2.4 mg | obesity | 68 | 3417 | −22.7 % vs −2.3 % Δ −20.4 pp | −20.4 % vs −3.0 % Δ −17.4 pp | — | 5.9 vs 3.5 | 11.8 vs 24.1 | — | — | 9.8 vs 6.1 | −9.9 vs −3.2 | verified |
| REDEFINE 2 | CagriSema 2.4/2.4 mg | t2d | 68 | 1206 | −15.7 % vs −3.1 % Δ −12.6 pp | −13.7 % vs −3.4 % Δ −10.3 pp | −1.8 vs −0.4 | 8.4 vs 3.0 | — | — | — | 10.4 vs 12.9 | −6.5 vs −2.4 | verified |
| REDEFINE 5 (vs semaglutide 2.4 mg) | CagriSema 2.4/2.4 mg vs semaglutide 2.4 mg: −11.9 % (efficacy) | obesity | 68 | 164 | −18.4 % | −16.9 % | −1.1 | 2.0 | 10.0 | — | — | 4.0 | −10.0 | verified |
| REDEFINE 9 | CagriSema 1.0/1.0 mg | obesity | 68 | — | −21.0 % vs −2.0 % Δ −19.0 pp | — | — | — | — | — | — | — | — | press release |
| REIMAGINE 1 (early T2D) | CagriSema 2.4/2.4 mg | t2d | 40 | 189 | −14.3 % vs −2.8 % Δ −11.5 pp | −14.3 % vs −2.8 % Δ −11.5 pp | — | — | — | — | — | — | — | verified |
| REIMAGINE 5 (vs tirzepatide 5 mg) | CagriSema 1.0/1.0 mg vs tirzepatide 5 mg (active) | t2d | 60 | — | −12.4 % | — | −1.7 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- CagriSema 2.4/2.4 mg: Any discontinuation = 100 − % still on drug at week 68.
- CagriSema 2.4/2.4 mg: Nausea, vomiting and per-arm discontinuation are in the supplementary appendix only.
- CagriSema 1.0/1.0 mg: Head-to-head vs tirzepatide 5 mg: weight −9.1 %, HbA1c −1.67 %-points (efficacy estimand); HbA1c non-inferior.
Verbatim quotes from the source (23)
- CagriSema 2.4/2.4 mg · weight_eff · Results, Efficacy, Body-Weight Reduction; Fig 1B
On the basis of the trial-product estimand, the percent weight reduction was −22.7% with cagrilintide–semaglutide and −2.3% with placebo
- CagriSema 2.4/2.4 mg · weight_tp · Table 2; Results, Efficacy
the mean percent body-weight reduction at week 68 was −20.4% with cagrilintide–semaglutide and −3.0% with placebo
- CagriSema 2.4/2.4 mg · ae_dc · Table 3; Results, Safety
discontinued because of adverse events (5.9% vs. 3.6%, 2.6%, and 3.5%, respectively)
- CagriSema 2.4/2.4 mg · sae · Table 3; Results, Safety
Serious adverse events were reported in 9.8% of the participants receiving cagrilintide–semaglutide
- CagriSema 2.4/2.4 mg · sbp · Table 2; Results, Additional End Points
The mean reduction from baseline to week 68 in systolic blood pressure was −9.9 mm Hg with cagrilintide–semaglutide and −3.2 mm Hg with placebo
- CagriSema 2.4/2.4 mg · disc_any · Results, Participants
The percentage of participants still receiving the drug or placebo at week 68 was 88.2% in the cagrilintide–semaglutide group, 91.4% in the semaglutide group, 87.7% in the cagrilintide group, and 75.9% in the placebo gro
- CagriSema 2.4/2.4 mg · weight_tp · Results, Body Weight (p.652); also Table 2 row 'Percent chan
For the treatment-policy estimand, the estimated mean change in body weight from baseline to week 68 (the first primary end point) was –13.7% with cagrilintide–semaglutide, as compared with –3.4% with placebo (estimated
- CagriSema 2.4/2.4 mg · weight_eff · Results, Body Weight (p.652); Fig. 1B; full table in Table S
For the trial-product estimand, the change in body weight was –15.7% with cagrilintide–semaglu- tide and –3.1% with placebo (estimated differ- ence, –12.6 percentage points; 95% CI, –13.4 to –11.7)
- CagriSema 2.4/2.4 mg · hba1c · Results, Glycemic-Related End Points (p.654); Table 2 row 'C
For the treatment-policy estimand, cagrilintide– semaglutide led to a greater mean reduction in the glycated hemoglobin level from baseline to week 68, as compared with placebo (–1.8 per- centage points vs. –0.4 percenta
- CagriSema 2.4/2.4 mg · sbp · Table 2 (p.652), confirmatory secondary end point; also Resu
Change in systolic blood pressure — mm Hg –6.5 –2.4 –4.1 (–6.0 to –2.1)
- CagriSema 2.4/2.4 mg · ae_dc · Table 3 (p.656) row 'Leading to permanent discontinuation —
Leading to permanent discontinuation Any adverse event 76 (8.4) 97 7.6 9 (3.0) 13 3.1
- CagriSema 2.4/2.4 mg · sae · Table 3 (p.656) row 'Serious'; Results, Safety (p.655)
Serious 94 (10.4) 138 10.8 39 (12.9) 51 12.1
- CagriSema 2.4/2.4 mg · weight_eff · Results, MRI sub-study
CagriSema reduced BW vs pbo (2.4 mg/2.4 mg: −14.3%; 1.0 mg/1.0 mg: −11.2%; pbo: −2.8%;
- CagriSema 2.4/2.4 mg · weight_eff · Table 2
Change in bodyweight† −18·4% −11·9% −6·5 (−8·4 to −4·6) <0·0001
- CagriSema 2.4/2.4 mg · weight_tp · Results, paragraph 4 (treatment policy estimand)
had a mean change in bodyweight of –16·9% (0·7) versus –11·1% (0·7) for semaglutide
- CagriSema 2.4/2.4 mg · ae_dc · Results, paragraph 10; Table 3
cagrilintide–semaglutide group (three [2%] participants) and the semaglutide group (four [2%]; table 3)
- CagriSema 2.4/2.4 mg · disc_any · Summary, Findings; Results paragraph 1
17 (10%) participants discontinued cagrilintide–semaglutide and ten (6%) discontinued semaglutide.
- CagriSema 2.4/2.4 mg · sae · Results, paragraph 10; Table 3
Serious adverse events were reported in six (4%) participants receiving cagrilintide–semaglutide and 11 (7%) receiving semaglutide
- CagriSema 2.4/2.4 mg · hba1c · Table 2
Change in HbA1c, %§ −1·1 −1·0 −0·1 (−0·2 to 0·0) 0·017
- CagriSema 2.4/2.4 mg · sbp · Table 2
Change in systolic blood pressure, mmHg§ −10·0 −5·2 −4·9 (−7·7 to −2·0) 0·0008
- CagriSema 1.0/1.0 mg · weight_eff · company announcement
CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss
- CagriSema 1.0/1.0 mg · hba1c · company announcement
1.71% (CagriSema) vs. 1.67% (tirzepatide) – non-inferior
- CagriSema 1.0/1.0 mg · weight_eff · company announcement
CagriSema 1.0 mg/1.0 mg provided a weight reduction of 21.0% versus 2.0%
Outcome trials
Ongoing outcome trials
| Trial | Molecule | Population | Primary endpoint | n | Registry status | Primary completion | Registry |
|---|---|---|---|---|---|---|---|
| REDEFINE 3 | CagriSema | Obesity + established CVD Obesity + established CVD, with or without T2D | 3-point MACE | 7101 | active not recruiting | 2027-09-01 | NCT05669755 |
Registered trials (25)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| REDEFINE A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity | Hypertension | Phase 3 | not yet recruiting | 2026-11 → 2028-06 | 1408 | not yet recruiting | NCT07919405 |
| NCT07817251 Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | T2D | Phase 3 | recruiting | 2026-09 → 2027-06 | 210 | recruiting | NCT07817251 |
| REIMAGINEYOUNG A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | T2D | Phase 3 | recruiting | 2026-08 → 2029-09 | 80 | recruiting | NCT07282613 |
| RENEW 4 A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Obesity | Phase 3 | recruiting | 2026-08 → 2027-05 | 285 | recruiting | NCT07745504 |
| NCT07564414 A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Obesity | Phase 3 | recruiting | 2026-05 → 2028-02 | 2500 | recruiting | NCT07564414 |
| NCT07253285 A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | Obesity | Phase 3 | recruiting | 2026-01 → 2030-03 | 460 | recruiting | NCT07253285 |
| RENEW 1 Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | Obesity | Phase 3 | active not recruiting | 2025-11 → 2027-05 | 300 | active not recruiting | NCT07220642 |
| RENEW 2 Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | Obesity | Phase 3 | active not recruiting | 2025-11 → 2027-05 | 330 | active not recruiting | NCT07220759 |
| NCT07011667 A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | Obesity | Phase 3 | active not recruiting | 2025-06 → 2027-03 | 609 | active not recruiting | NCT07011667 |
| NCT06780449 A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity | Obesity | Phase 3 | active not recruiting | 2025-02 → 2028-08 | 400 | active not recruiting | NCT06780449 |
| NCT06797869 A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | Neurology | Phase 2 | completed | 2025-01 → 2026-06 | 142 | Completed; results not in the atlas yet | NCT06797869 |
| REIMAGINE 5 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | T2D | Phase 3 | completed | 2024-11 → 2026-06 | 1023 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT06534411 |
| NCT06388187 A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight | Obesity | Phase 3 | completed | 2024-06 → 2026-04 | 300 | Completed; results not in the atlas yet | NCT06388187 |
| NCT06409130 Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease | Other | Phase 2 | completed | 2024-05 → 2025-11 | 270 | Completed; results not in the atlas yet | NCT06409130 |
| NCT06131372 A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | CKD | Phase 2 | completed | 2024-04 → 2025-09 | 626 | Completed; results not in the atlas yet | NCT06131372 |
| REIMAGINE 3 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin | T2D | Phase 3 | completed | 2024-03 → 2025-09 | 274 | Completed; results not in the atlas yet | NCT06323161 |
| REIMAGINE 1 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | T2D | Phase 3 | completed | 2024-03 → 2025-10 | 189 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT06323174 |
| REIMAGINE 4 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | T2D | Phase 3 | completed | 2024-01 → 2026-03 | 1024 | Completed; results not in the atlas yet | NCT06221969 |
| REDEFINE 4 A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | Obesity | Phase 3 | completed | 2023-11 → 2025-12 | 809 | Weight non-inferiority vs tirzepatide 15 mg not met: −20.2 % vs −23.6 % (treatment-regimen), −23.0 % vs −25.5 % (efficacy); topline press release, Feb 2026 | NCT06131437 |
| REIMAGINE 2 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | T2D | Phase 3 | completed | 2023-09 → 2025-11 | 2734 | Completed; results not in the atlas yet | NCT06065540 |
| REDEFINE 6 A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight | Obesity | Phase 3 | completed | 2023-08 → 2025-01 | 300 | Completed; results not in the atlas yet | NCT05996848 |
| REDEFINE 5 A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight | Obesity | Phase 3 | completed | 2023-04 → 2025-01 | 331 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05813925 |
| REDEFINE 3 REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | CV outcomes | Phase 3 | active not recruiting | 2023-03 → 2027-09 | 7101 | NCT05669755 | |
| REDEFINE 2 A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight | Obesity | Phase 3 | completed | 2023-02 → 2025-01 | 1200 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05394519 |
| REDEFINE 1 A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | Obesity | Phase 3 | active not recruiting | 2022-11 → 2024-10 | 3400 | active not recruiting | NCT05567796 |
Primary sources
- Novo Nordisk A/S. Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity (REDEFINE 1). ClinicalTrials.gov identifier NCT05567796. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05567796
- Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-647. PMID: 40544433.
- Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-659. PMID: 40544432.
- Novo Nordisk A/S. Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). ClinicalTrials.gov identifier NCT05394519. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05394519
- Jøran Hjelmesæth et al. Efficacy of CagriSema on body composition in participants with early type 2 diabetes: REIMAGINE 1. Abstract LBA 11. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: LBA OP 02 New and old drugs: reproductive or metabolic relevance]
- Yamauchi T, Becker NP, Hagemann CA, Huang KC, Kiyosue A, Lim S, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2026;14(6):450-462. PMID: 42009015.
- Novo Nordisk. CagriSema REIMAGINE 5 and REDEFINE 9 topline results [company announcement]. 2026 Sep 21. Available from: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916774
- Novo Nordisk A/S. The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease (REDEFINE 3). ClinicalTrials.gov identifier NCT05669755. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05669755
How to cite this page
Cite the primary publication for any single result; every value above links to it.